Vaxart, Inc. - Common StockNASDAQ
Description
⋅ This month, VXRT is awaiting results for their Stage 1 clinical trial for COVID vaccine. It is a single dose tablet and not an injection..
If approved, the chart suggests a push to at least the next fib level to $8.27 and another possible move to the $10 range.
It is currently in a descending triangle with a 28.5% short float.
This is not advice, do your own DD.
seekingalpha.com/article/4397483-vaxarts-oral-covidminus-19-vaccine-be-2021-biotech-highlight